TriangleBiospecimen Collection (NCT07780838)
Biospecimen Collection trial for Locally Advanced Ampulla of Vater Carcinoma (NCT07780838). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with unresectable advanced or metastatic biliary-tract cancer and a qualifying FGFR alteration. Eligible sites: bile ducts, gallbladder and ampulla. One initial chemotherapy cycle is allowed; prior FGFR-targeted treatment is excluded.
The idea: alternate intravenous gemcitabine, cisplatin and durvalumab with oral pemigatinib. Chemotherapy damages cancer cells, durvalumab supports immune attack, and pemigatinib blocks FGFR growth signals. Treatment switches between two chemoimmunotherapy cycles and three pemigatinib cycles. Researchers assess survival and safety.
This phase 2 study plans 29 patients. Ohio State leads it in Columbus, the only recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.